Skip to main content

Advertisement

SpringerLink
Log in

A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

A panel of cytolytic T lymphocyte (CTL) clones was isolated from metastases and blood samples of a melanoma patient vaccinated with MAGE-3.A1-pulsed autologous dendritic cells. We report here the identification of a new antigen encoded by the MAGE-C2 cancer-germline gene. This antigen is recognized by some of these CTL on HLA-B*4403. The sequence of the peptide is SESIKKKVL. It is processed in various melanoma cell lines expressing MAGE-C2 and HLA-B*4403. Because of the expression pattern of gene MAGE-C2, this new antigen is strictly tumor-specific and could therefore be used for peptide-based antitumoral vaccination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M (1980) Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815 II T lymphocyte-mediated cytolysis. J Exp Med 152:1184–1193

    Article  PubMed  CAS  Google Scholar 

  2. Boon T, Coulie PG, Van den Eynde B, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:6.1–6.34

    Article  Google Scholar 

  3. Brasseur F (1999) Melanoma: Brussels Melanoma cell lines. In: Masters JRW, Palsson B (eds) Human cell culture, vol 1. Kluwer, Dordrecht, pp 275–282

  4. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S (2001) An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 61:5544–5551

    PubMed  CAS  Google Scholar 

  5. Espevik T, Nissen-Meyer J (1986) A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95:99–105

    Article  PubMed  CAS  Google Scholar 

  6. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethé B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921–930

    Article  PubMed  CAS  Google Scholar 

  7. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethé B, De Plaen E, Velu T, Coulie PG (2005) High frequency of anti-tumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201:241–248

    Article  PubMed  CAS  Google Scholar 

  8. Godelaine D, Carrasco J, Lucas S, Karanikas V, Schuler-Thurner B, Coulie PG, Schuler G, Boon T, Van Pel A (2003) Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol 171:4893–4897

    PubMed  CAS  Google Scholar 

  9. Haas GG Jr, D’Cruz OJ, De Bault LE (1988) Distribution of human leukocyte antigen-ABC and -D/DR antigens in the unfixed human testis. Am J Reprod Immunol Microbiol 18:47–51

    PubMed  Google Scholar 

  10. Herman J, Jongeneel V, Kuznetsov D, Coulie PG (1999) Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid. Tissue Antigens 53:111–121

    Article  PubMed  CAS  Google Scholar 

  11. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T (1991) Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T (eds) XIth international histocompatibility workshop and conference, vol 1. Oxford University Press, New York, p 1065

  12. Jäger E, Chen Y-T, Drijfhout JW, Karbach J, Ringhoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265–270

    Article  PubMed  Google Scholar 

  13. Lee TD (1990) Distributions of HLA antigens. In: Lee J (ed) The HLA system A new approach. Springer, Berlin Heidelberg New York, pp 141–178

    Google Scholar 

  14. Lucas S, De Plaen E, Boon T (2000) MAGE-B5, MAGE-B6, MAGE-C2 and MAGE-C3: four new members of the MAGE family with tumor-specific expression. Int J Cancer 87:55–60

    Article  PubMed  CAS  Google Scholar 

  15. Lurquin C, Lethé B, Corbière V, Théate I, van Baren N, Coulie PG, Boon T (2005) Contrasting frequencies of anti-tumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201:249–257

    Article  PubMed  CAS  Google Scholar 

  16. Ma W, Germeau C, Vigneron N, Maernoudt A-S, Morel S, Boon T, Coulie PG, Van den Eynde B (2004) Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2. Int J Cancer 109:698–702

    Article  PubMed  CAS  Google Scholar 

  17. Rimoldi D, Rubio-Godoy V, Dutoit V, Liénard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini J-C, Lejeune F, Romero P, Valmori D (2000) Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol 165:7253–7261

    PubMed  CAS  Google Scholar 

  18. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915

    Article  PubMed  CAS  Google Scholar 

  19. Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P (2000) A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 60:6272–6275

    PubMed  CAS  Google Scholar 

  20. Traversari C, van der Bruggen P, Van den Eynde B, Hainaut P, Lemoine C, Ohta N, Old L, Boon T (1992) Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35:145–152

    Article  PubMed  CAS  Google Scholar 

  21. Tynan FE, Elhassen D, Purcell AW, Burrows JM, Borg NA, Miles JJ, Williamson NA, Green KJ, Tellam J, Kjer-Nielsen L, McCluskey J, Rossjohn J, Burrows SR (2005) The immunogenicity of a viral cytotoxic T cell epitope is controlled by its MHC-bound conformation. J Exp Med 202:1249–1260

    Article  PubMed  CAS  Google Scholar 

  22. Van den Eynde B, van der Bruggen P. Peptide database of T-cell defined tumor antigens. URL: http://www.cancerimmunity.org/peptidedatabase/Tcellepitopes.htm

  23. van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51–64

    Article  Google Scholar 

Download references

Acknowledgments

We thank V. Ha Thi, M. Panagiotakopoulos and M. Swinarska for technical assistance, W. Ma for providing the MAGE-C2 minigenes, and V. Stroobant for peptide synthesis. We thank P. van der Bruggen for critical reading, and N. Krack for editorial assistance. This work was supported by the Belgian Programme on Interuniversity Poles of Attraction initiated by the Belgian State, Prime Minister’s Office, Science Policy Programming, and by a grant of the Fédération Belge contre le Cancer. Javier Carrasco was supported by a grant FNRS-TELEVIE.

Author information

Authors and Affiliations

  1. Ludwig Institute for Cancer Research, 74 avenue Hippocrate, UCL 7459, 1200, Brussels, Belgium

    Danièle Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon & Aline Van Pel

  2. Institute of Cellular Pathology, Cellular Genetics Unit, Université Catholique de Louvain, 74 avenue Hippocrate, UCL 7459, 1200, Brussels, Belgium

    Danièle Godelaine, Javier Carrasco, Francis Brasseur, Thierry Boon & Aline Van Pel

  3. Department of Medical Oncology, Oncology Center, AZ-VUB, 101 Laarbeeklaan, 1090, Brussels, Belgium

    Bart Neyns

  4. Laboratory of Physiology, Vrije Universiteit Brussel Faculty of Medicine, 103 Laarbeeklaan, 1090, Brussels, Belgium

    Kris Thielemans

Authors
  1. Danièle Godelaine
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Carrasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Francis Brasseur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bart Neyns
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kris Thielemans
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thierry Boon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Aline Van Pel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aline Van Pel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Godelaine, D., Carrasco, J., Brasseur, F. et al. A new tumor-specific antigen encoded by MAGE-C2 and presented to cytolytic T lymphocytes by HLA-B44. Cancer Immunol Immunother 56, 753–759 (2007). https://doi.org/10.1007/s00262-006-0244-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-006-0244-5

Keywords

Search

Navigation